113 filings
Page 3 of 6
8-K
n510ck yp
14 Nov 22
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
8:21am
8-K
trbhxqv6jr
9 Aug 22
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
8:02am
8-K
dujp2hha6pv
21 Jun 22
Submission of Matters to a Vote of Security Holders
8:00am
8-K
7f8xuf6m9oro
10 May 22
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
8:05am
DEFA14A
jdfxfnd1 5xsudak1
29 Apr 22
Additional proxy soliciting materials
8:01am
8-K
owlu91fdp2ficd
8 Apr 22
Departure of Directors or Certain Officers
4:30pm
S-8
z6i99dxyigx5
17 Mar 22
Registration of securities for employees
4:31pm
8-K
lnnnez1rshyq6e122i8c
16 Mar 22
Prelude Therapeutics Reports Full Year 2021 Financial Results
8:05am
8-K
6nkk2u4fip7ibvd9l74
9 Mar 22
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
8:22am
8-K
axczzfov 62xdevzk3l
16 Feb 22
Regulation FD Disclosure
5:03pm
8-K
nr7pv f733fs99t97
10 Jan 22
Regulation FD Disclosure
7:02am
8-K
7j821993pbtgdkm0b4
3 Dec 21
Entry into a Material Definitive Agreement
9:00am
EFFECT
ogyyi5rrjmy o5p
26 Nov 21
Notice of effectiveness
12:15am
CORRESP
7rc3oce5
22 Nov 21
Correspondence with SEC
12:00am
UPLOAD
qdzcw
19 Nov 21
Letter from SEC
12:00am